LQDA Liquidia Corporation

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

The live webcast will be available on Liquidia's website at . A rebroadcast of the event will be available and archived for a period of one year at the same location.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit .

Contact Information

Investors:

Jason Adair

Chief Business Officer

919.328.4350



Media:

Patrick Wallace

Director, Corporate Communications

919.328.4383



EN
12/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Liquidia Corporation

 PRESS RELEASE

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Vi...

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the “Investor...

 PRESS RELEASE

Liquidia Corporation to Present at the 24th Annual Needham Virtual Hea...

Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the “Investors” page of Liquidi...

 PRESS RELEASE

Liquidia Corporation Announces FDA Acceptance of New Drug Application ...

Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder FDA sets PDUFA goal date of May 24, 2025 MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pul...

 PRESS RELEASE

Liquidia Announces Poster Presentations at the American Thoracic Socie...

Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference - Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life - Case study highlights the long-term safety and tolerability of LIQ861 (YUTREPIA) in a PAH patient transitioning from parenteral treprostinil in INSPIRE study MORRISVILLE, N.C., March 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company ...

 PRESS RELEASE

Liquidia Corporation Reports Full Year 2024 Financial Results and Prov...

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil products in clinical studiesStrengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty Partners (HCRx)Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch